SAN DIEGO, Sept. 25, 2025 — The U.S. Food and Drug Administration (FDA) has approved PALSONIFY™ (paltusotine) as the first once-daily, oral treatment for acromegaly in adults who are not eligible for surgery or have had an inadequate response. Approval was based on positive outcomes from the PATHFNDR-1 and PATHFNDR-2 Phase 3 trials, which demonstrated rapid, durable, and consistent biochemical control alongside reduced symptom burden.
Science Significance
Paltusotine is a selectively targeted nonpeptide somatostatin receptor type 2 (SST2) agonist. Unlike traditional injectable therapies, it delivers oral, reliable control of insulin-like growth factor 1 (IGF-1) levels and significantly improves symptoms such as headaches, fatigue, joint pain, and swelling. The approval establishes a new treatment paradigm in endocrinology, offering effective disease management with improved convenience.
Regulatory Significance
The FDA approval marks a regulatory breakthrough as the first oral therapy for acromegaly. It highlights regulators’ recognition of the therapy’s strong safety and efficacy data. A Marketing Authorization Application (MAA) for paltusotine is also under review in the European Union, with a Committee for Medicinal Products and Human Use (CHMP) opinion expected in 2026, signaling potential global expansion.
Business Significance
Advertisement
The launch of PALSONIFY is a pivotal milestone for its developer, transforming it into a commercial-stage company with a leading product in endocrinology. The U.S. approval strengthens its competitive position in the rare disease market, while ongoing programs for carcinoid syndrome expand the therapy’s commercial potential across related conditions.
Patients’ Significance
For patients, FDA approval of PALSONIFY provides a long-awaited oral alternative to burdensome injections. This innovation reduces treatment barriers, offering better quality of life and sustained disease control. Patients also benefit from improved treatment adherence and independence, which may lead to better long-term outcomes.
Policy Significance
This approval underscores the importance of regulatory incentives and rare disease frameworks that accelerate access to innovative therapies. By enabling development of first-in-class oral treatments, health policies play a vital role in ensuring equitable access for patients with chronic and rare conditions like acromegaly.
The FDA approval of PALSONIFY (paltusotine) marks a historic advance in acromegaly care. By delivering safe, effective, and convenient oral therapy, this milestone redefines treatment standards, expands patient access, and strengthens the foundation for future innovation in rare endocrine diseases.
Source: Crinetics press release
